Epidermal growth factor receptor mutations in lung adenocarcinoma - Siegelin, Markus D; Borczuk, Alain C (Laboratory investigation, 2014)
Keywords: 631/208/737; 692/420/755; 692/699/67/1059/2326; 692/699/67/1612; Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma of Lung; Drug Resistance, Neoplasm - genetics; Drug Resistance, Neoplasm - physiology; epidermal growth factor receptor; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - physiology; Gefitinib; Gene Expression Regulation, Neoplastic - genetics; Gene Expression Regulation, Neoplastic - physiology; Humans; Laboratory Medicine; lung adenocarcinoma; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; MAP Kinase Kinase 1 - genetics; MAP Kinase Kinase 1 - metabolism; Medicine; Medicine & Public Health; Models, Biological; Mutation - genetics; mutations; pathobiology-in-focus; Pathology; Protein Kinase Inhibitors - therapeutic use; Quinazolines - pharmacology; Quinazolines - therapeutic use; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; resistance mutations; Signal Transduction - physiology; tyrosine kinase inhibitors; tyrosine kinase inhibitors; mutations; epidermal growth factor receptor; resistance mutations; lung adenocarcinoma